Targets › IL17F
2 programs from 2 companies in 11 trials: 8 Phase 3, 2 Phase 1, 1 Phase 2; Immunology, Infectious disease; next expected readout Dec 2026.
Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. (UniProt, Q96PD4)
Open in Phaseline: the race on IL17F, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| UCB Biopharma SRL | Bimekizumab Interleukin 17A inhibitor; Interleukin-17F inhibitor | IL17A, IL17F | Phase 3 | Hidradenitis Suppurativa; Moderate to Severe Plaque Psoriasis; Palmoplantar Pustulosis; Enthesitis-related Arthritis … | Dec 2026 |
| MoonLake Immunotherapeutics | M-1095 Interleukin 17A inhibitor; Interleukin-17F inhibitor | IL17A, IL17F | Phase 3 | Hidradenitis Suppurativa; Arthritis, Psoriatic | Jan 2027 |
Moderate to Severe Plaque Psoriasis (3) Hidradenitis Suppurativa (2) Arthritis, Psoriatic (2) Palmoplantar Pustulosis (1) Enthesitis-related Arthritis (1) Psoriatic Arthritis (1) Psoriasis (1)
antibody (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.